Lunit announced on the 3rd that the number of medical institutions adopting its artificial intelligence (AI) imaging diagnostic solution has surpassed 10,000 worldwide. The adoption of Lunit products has occurred in the United States, Asia, Oceania, Europe, Latin America, the Middle East, and Africa. Lunit introduced its chest X-ray AI imaging analysis solution, 'Lunit Insight CXR,' and its mammography AI imaging analysis solution, 'Lunit Insight MMG,' in 2019.
Medytox announced on the 3rd that it has selected actor Park Hyung-sik as a global ambassador. The company plans to conduct a new advertising campaign for its hyaluronic acid filler, Newramis, which is celebrating its 12th anniversary, across various channels including TV, print (magazines), and YouTube. New advertisements, behind-the-scenes footage, and shorts will be released sequentially on its official YouTube channel.
Celltrion announced on the 3rd that the biosimilar 'CT-P44' of 'Dazalex' has received approval for its phase 3 clinical trial plan from the Ministry of Food and Drug Safety. Dazalex is an anti-cancer drug for multiple myeloma, a type of blood cancer, targeting specific proteins present on the surface of multiple myeloma cells. The company plans to compare the efficacy and safety of Dazalex and CT-P44 in a trial involving 486 participants.
Korea University Ansan Hospital's neurosurgery brain tumor division announced on the 3rd that it has recorded a cumulative total of 1,200 brain tumor surgeries. With a professor on staff, it treats various diseases in both adults and pediatric patients. Recently, endoscopic approaches for skull base surgery have been performed. High-precision radiosurgery, which irradiates tumors without incisions, is also being conducted.
GC Labs announced on the 3rd that it has launched an automated testing laboratory system at its Yongin Diagnostic Center. The system has automated all processes from sample classification to analysis. The system is called Labinno, which signifies lab innovation.
Daewoong announced on the 3rd that it will showcase 'Daewoong Healthcare' at the 2025 International Safety and Health Exhibition. It is a customized health management solution for its employees, aimed at managing their physical, mental, and metabolic health and providing health check-up services.
Daewoong Pharmaceutical announced on the 3rd that it held 11 symposiums in eight cities nationwide to commemorate the launch of 'StoboClo.' StoboClo is a denosumab biosimilar that aids in the treatment of osteoporosis. A total of 720 medical professionals participated in the symposiums.